Sionna Therapeutics, Inc. (SION) Stock Price & Analysis
Sionna Therapeutics, Inc. (SION) rose 1.67% to USD 7.3 as of September 9, 2026 at 10:11 UTC, according to Nexqual real-time market data.
SION last closed at USD 7.18; the session ranged USD 6.89–7.56 on volume of 883,782 shares. Market capitalization is $329.60M, with a 52-week range of USD 4.01–54.97 (NGM). Source: Nexqual, September 9, 2026 at 10:11 UTC.
Key Statistics (as of September 9, 2026 at 10:11 UTC)
| Price | USD 7.3 |
|---|---|
| Change | ▲ 1.67% (up) |
| Previous Close | USD 7.18 |
| Open | USD 7.13 |
| Day Range | USD 6.89 – 7.56 |
| 52-Week Range | USD 4.01 – 54.97 |
| Volume | 883,782 shares |
| Market Cap | $329.60M |
| Exchange | NGM |
Technical Analysis (SION)
Nexqual's technical model rates SION "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of September 9, 2026 at 10:11 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.52 (oversold) |
| vs SMA50 | Below (USD 29.1) |
| MACD | -6.41 (negative) |
Analyst Ratings (SION)
Wall Street analysts rate SION "None" based on 6 analysts, with a mean price target of USD 15.17 (range USD 5–63), per Nexqual as of September 9, 2026 at 10:11 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 15.17 |
| High Target | USD 63 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 1 / 10 / 0 |
Earnings (SION)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.67 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.66 vs est -0.65 ▼ miss |
| 2026-03-31 | USD -0.6 vs est -0.5 ▼ miss |
| 2025-12-31 | USD -0.46 vs est -0.54 ▲ beat |
| 2025-09-30 | USD -0.46 vs est -0.48 ▲ beat |
Source: Nexqual, September 9, 2026 at 10:11 UTC.
Financials & Fundamentals (SION)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -32.34% |
| Debt / Equity | 3.04 |
| Current Ratio | 20.05 |
| Total Cash | $211.03M |
| Total Debt | $8.07M |
| Free Cash Flow | $-45.44M |
Source: Nexqual, September 9, 2026 at 10:11 UTC.
Financial Health Score (SION)
Nexqual rates Sionna Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of September 9, 2026 at 10:11 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $211M cash vs $8M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$76M |
| Efficiency | Critical — ROE -32%, ROA -21.5% |
Ownership (SION)
| Insider Ownership | +6.84% |
|---|---|
| Institutional Ownership | +107.20% |
| Shares Outstanding | 45.15M |
| Float | 17.03M |
| Short % of Float | +15.24% |
Source: Nexqual, September 9, 2026 at 10:11 UTC.
Leadership (SION)
Sionna Therapeutics, Inc. is led by Michael Cloonan (age 53), President, CEO & Director, per Nexqual as of September 9, 2026 at 10:11 UTC.
| President, CEO & Director | Michael Cloonan (age 53) |
|---|---|
| Chief Financial Officer | Elena H. Ridloff C.F.A. (age 45) |
Major Backers & Investors (SION)
Notable institutional backers of Sionna Therapeutics, Inc. include RA Capital Management, L.P., TPG GP A, LLC, Viking Global, according to Nexqual as of September 9, 2026 at 10:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 21.91% |
| TPG GP A, LLC | 14.37% |
| Viking Global | 7.07% |
| Atlas Venture Life Science Advisors, LLC | 6.63% |
| Orbimed Advisors LLC. | 5.65% |
| Enavate Sciences Gp, LLC | 5.48% |
| JPMorgan | 4.46% |
| Adage Capital Partners GP L.L.C. | 3.54% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.33% |
Source: Nexqual, September 9, 2026 at 10:11 UTC.
From Sionna Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- We have developed a broad patent estate and expect to expand and protect our proprietary know-how and intellectual property.
- While we have prioritized development of a proprietary dual combination, we believe both development pathways offer attractive commercial opportunities. 10 Table of Contents Figure 1 Our Pipeline The following table summarizes our clinical stage pipeline: Figure 2 Our proprietary portfolio is anchored by our NBD1 stabilizers and our complementary modulators.
- We believe the model allows us to determine the target exposure needed to achieve a desired level of clinical activity, such as the level of improvement in a patient's forced expiratory volume in one second ("FEV 1" ), a measure of lung function, and sweat chloride level, the clinical biomarker of CFTR function.
- Our Approach and Leveraging the CFHBE Model Our programs leverage an industry standard, clinically predictive CFHBE model to measure CFTR protein function in vitro.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MAZE | Maze Therapeutics, Inc. | USD 26.37 | ▲ 1.93% |
| BCAX | Bicara Therapeutics Inc. | USD 23.71 | ▲ 1.59% |
| MPLT | MapLight Therapeutics, Inc. | USD 13.95 | ▲ 6.16% |
| ALMS | Alumis Inc. | USD 10.58 | ▼ 6.87% |
| MBX | MBX Biosciences, Inc. | USD 62.99 | ▲ 2.56% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 10:11 UTC. This page is informational and not investment advice.